Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#11 / 99 Total
VWE - Vintage Wine Estates Inc - Stock Price Chart
TickerVWE [NASD]
CompanyVintage Wine Estates Inc
CountryUSA
IndustryBeverages - Wineries & Distilleries
Market Cap11.98MEPS (ttm)-2.06
P/E-EPS this Y19.44%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.04EPS next 5Y-
P/B0.11EPS Q/Q62.41%
Dividend-Sales Q/Q-12.83%
Insider Own48.05%Inst Own17.58%
Insider Trans1.08%Inst Trans-6.66%
Short Float1.05%EarningsMar 12/a
Analyst Recom1.00Target Price1.00
Avg Volume169.91K52W Range0.22 - 1.45
Vintage Wine Estates, Inc. operates as a vintner, which offers a collection of wines, heritage wineries, lifestyle wines, new wine brands and packaging concepts, as well as craft spirits. It operates through the following segments: Wholesale, Business-to-Business, and Direct-to-Consumer. The company was founded by Patrick Roney in 2019 and is headquartered in Incline Village, NV.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Roney Patrick AExecutive ChairmanDec 13 '23Buy0.53100,00053,000410,400Dec 15 04:30 PM
Proctor Timothy DDirectorNov 30 '23Buy0.571,8021,027143,295Dec 01 04:29 PM
Proctor Timothy DDirectorNov 29 '23Buy0.5730,05017,128141,493Dec 01 04:29 PM
Proctor Timothy DDirectorNov 28 '23Buy0.5717,3449,886111,443Nov 29 04:31 PM
Proctor Timothy DDirectorNov 27 '23Buy0.5620,23611,33294,099Nov 29 04:31 PM
ZVSA - ZyVersa Therapeutics Inc - Stock Price Chart
TickerZVSA [NASD]
CompanyZyVersa Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap3.79MEPS (ttm)-71.31
P/E-EPS this Y98.62%
Forward P/E-EPS next Y-206.98%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B0.18EPS Q/Q-6291.81%
Dividend-Sales Q/Q-
Insider Own1.17%Inst Own137.53%
Insider Trans0.00%Inst Trans-
Short Float-EarningsMar 25/b
Analyst Recom1.00Target Price80.00
Avg Volume246.92K52W Range5.00 - 220.85
Apr-04-24 07:57AM ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes (GlobeNewswire)
Mar-25-24 08:17AM ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-18-24 07:57AM ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease (GlobeNewswire) +8.79%
Mar-14-24 07:57AM ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled Inflammation Illuminated, at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024 (GlobeNewswire)
Feb-29-24 07:57AM ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity (GlobeNewswire) +10.00%
Feb-28-24 07:57AM ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications (GlobeNewswire) -8.26%
Feb-26-24 07:55AM Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today? (InvestorPlace) +34.83%
Feb-22-24 07:47AM ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option (GlobeNewswire)
Feb-14-24 07:53AM ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases (GlobeNewswire)
Feb-07-24 08:02AM ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones (GlobeNewswire)
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.
HYW - Hywin Holdings Ltd ADR - Stock Price Chart
TickerHYW [NASD]
CompanyHywin Holdings Ltd ADR
CountryChina
IndustryAsset Management
Market Cap23.73MEPS (ttm)0.63
P/E1.34EPS this Y-
Forward P/E-EPS next Y-
PEG0.30EPS past 5Y24.00%
P/S0.08EPS next 5Y4.53%
P/B0.16EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own-Inst Own0.79%
Insider Trans-Inst Trans1.72%
Short Float-Earnings-
Analyst Recom1.00Target Price12.01
Avg Volume21.73K52W Range0.79 - 7.50
Hywin Holdings Ltd. engages in the provision of financial services. Its services include wealth management, insurance brokerage, and asset management. The company was founded by Hongwei Han in July 19, 2019 and is headquartered in Shanghai, China.
DRTS - Alpha Tau Medical Ltd - Stock Price Chart
TickerDRTS [NASD]
CompanyAlpha Tau Medical Ltd
CountryIsrael
IndustryBiotechnology
Market Cap167.56MEPS (ttm)-0.42
P/E-EPS this Y-21.37%
Forward P/E-EPS next Y-9.11%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.98EPS Q/Q-115.27%
Dividend-Sales Q/Q-
Insider Own26.33%Inst Own2.52%
Insider Trans0.00%Inst Trans3.00%
Short Float0.08%EarningsMar 07/a
Analyst Recom1.00Target Price9.25
Avg Volume32.51K52W Range2.40 - 4.80
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.
ATXI - Avenue Therapeutics Inc - Stock Price Chart
TickerATXI [NASD]
CompanyAvenue Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap3.66MEPS (ttm)4.87
P/E1.27EPS this Y58.16%
Forward P/E-EPS next Y9.76%
PEG-EPS past 5Y50.07%
P/S-EPS next 5Y-
P/B1.34EPS Q/Q358.44%
Dividend-Sales Q/Q-
Insider Own11.82%Inst Own-
Insider Trans-10.55%Inst Trans-
Short Float0.01%EarningsMar 18/a
Analyst Recom1.00Target Price56.25
Avg Volume24.43K52W Range6.39 - 93.75
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Davidow Robert L10% OwnerDec 11 '23Sale0.14353,00049,60022,000Dec 13 04:02 PM
Davidow Robert L10% OwnerDec 11 '23Sale0.14264,00036,960681,000Dec 13 04:02 PM
Fortress Biotech, Inc.10% OwnerSep 08 '23Buy0.72418,410301,2551,032,390Sep 12 09:02 AM
ROSENWALD LINDSAY A MDDirectorSep 08 '23Buy0.72348,675251,046354,318Sep 12 09:03 AM
INM - InMed Pharmaceuticals Inc - Stock Price Chart
TickerINM [NASD]
CompanyInMed Pharmaceuticals Inc
CountryCanada
IndustryBiotechnology
Market Cap0.77MEPS (ttm)-1.65
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y39.17%
P/S0.14EPS next 5Y-
P/B0.10EPS Q/Q79.70%
Dividend-Sales Q/Q163.99%
Insider Own1.56%Inst Own24.17%
Insider Trans152.27%Inst Trans14.36%
Short Float3.49%EarningsFeb 13/b
Analyst Recom3.00Target Price20.00
Avg Volume371.29K52W Range0.25 - 2.08
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. It operates through the InMed and BayMedica segments. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HULL ANDREWDirectorFeb 21 '24Buy0.3937,50014,62538,258Feb 22 01:38 PM
ADAMS ERIC APresident & CEOFeb 20 '24Buy0.3641,60014,92243,959Feb 21 02:58 PM
GTBP - GT Biopharma Inc - Stock Price Chart
TickerGTBP [NASD]
CompanyGT Biopharma Inc
CountryUSA
IndustryBiotechnology
Market Cap4.62MEPS (ttm)-5.57
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y70.75%
P/S-EPS next 5Y-
P/B0.62EPS Q/Q58.10%
Dividend-Sales Q/Q-
Insider Own10.42%Inst Own92.43%
Insider Trans0.00%Inst Trans-86.24%
Short Float0.26%EarningsNov 01/b
Analyst Recom1.00Target Price150.00
Avg Volume13.66K52W Range3.52 - 16.11
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.
VAXX - Vaxxinity Inc - Stock Price Chart
TickerVAXX [NASD, RUT]
CompanyVaxxinity Inc
CountryUSA
IndustryBiotechnology
Market Cap14.78MEPS (ttm)-0.45
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-41.17%
P/S-EPS next 5Y-
P/B1.10EPS Q/Q44.61%
Dividend-Sales Q/Q-
Insider Own64.25%Inst Own9.89%
Insider Trans0.00%Inst Trans0.48%
Short Float9.32%EarningsMar 27/a
Analyst Recom2.00Target Price7.00
Avg Volume695.47K52W Range0.12 - 3.10
Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company uses its synthetic peptide vaccine platform to harness the immune system and convert the body into its own 'drug factory', stimulating the production of antibodies with a therapeutic effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer's, Parkinson's, migraine and hypercholesterolemia as well as a candidate for COVID-19 prevention. The company was founded by Louis G. Reese IV and Mei Mei Hu in 2014 and is headquartered in Exploration Park, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Prime Movers Lab Fund I LP10% OwnerSep 08 '23Sale1.6725,08941,8998,713,663Sep 08 06:05 PM
Prime Movers Lab Fund I LP10% OwnerSep 08 '23Sale1.6722,87238,196831,658Sep 08 06:05 PM
Prime Movers Lab Fund I LP10% OwnerSep 07 '23Sale1.7920,31236,3028,738,752Sep 08 06:05 PM
Prime Movers Lab Fund I LP10% OwnerSep 07 '23Sale1.7918,51633,092834,053Sep 08 06:05 PM
Prime Movers Lab Fund I LP10% OwnerSep 06 '23Sale1.885,3089,9918,759,064Sep 08 06:05 PM
SYPR - Sypris Solutions, Inc. - Stock Price Chart
TickerSYPR [NASD]
CompanySypris Solutions, Inc.
CountryUSA
IndustryAuto Parts
Market Cap31.36MEPS (ttm)-0.07
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y15.64%
P/S0.23EPS next 5Y8.00%
P/B1.40EPS Q/Q-868.75%
Dividend-Sales Q/Q16.91%
Insider Own46.73%Inst Own45.32%
Insider Trans0.00%Inst Trans143.01%
Short Float4.65%EarningsApr 01/b
Analyst Recom3.00Target Price1.25
Avg Volume28.61K52W Range1.38 - 2.30
Sypris Solutions, Inc. engages in the provision of truck components, oil and gas pipeline components, and aerospace and defense electronics. It operates through Sypris Technologies and Sypris Electronics segments. The Sypris Technologies segment is involved in selling of forged, machined, welded, and heat-treated steel components primarily for the heavy commercial vehicle and high-pressure energy pipeline applications. The Sypris Electronics segment includes circuit card and full box build manufacturing, high reliability manufacturing, systems assembly and integration, design for manufacturability and design to specification work. The company was founded in 1997 and is headquartered in Louisville, KY.
CHTR - Charter Communications Inc. - Stock Price Chart
TickerCHTR [NASD, NDX, S&P 500]
CompanyCharter Communications Inc.
CountryUSA
IndustryTelecom Services
Market Cap36.76BEPS (ttm)30.91
P/E8.24EPS this Y11.01%
Forward P/E7.27EPS next Y5.14%
PEG0.79EPS past 5Y41.86%
P/S0.67EPS next 5Y10.49%
P/B3.09EPS Q/Q13.42%
Dividend-Sales Q/Q0.19%
Insider Own32.32%Inst Own70.86%
Insider Trans-0.69%Inst Trans-3.55%
Short Float12.50%EarningsApr 26/b
Analyst Recom2.57Target Price351.32
Avg Volume1.70M52W Range254.31 - 458.30
Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jacobson Craig ADirectorFeb 28 '24Sale289.24918265,5189,331Mar 01 04:32 PM
Winfrey Christopher LPresident and CEOFeb 06 '24Buy295.295,0501,491,21457,703Feb 07 04:12 PM
Winfrey Christopher LPresident and CEOJan 12 '24Option Exercise150.8828,9114,362,09272,814Jan 17 04:34 PM
Winfrey Christopher LPresident and CEOJan 12 '24Option Exercise150.888,0651,216,84746,450Jan 17 04:34 PM
Rutledge ThomasExecutive ChairmanNov 17 '23Sale410.8283,97034,496,6110Nov 20 04:34 PM
12345678910